The Sept. 12 series A funding round helped launch Pretzel Therapeutics, which aims to develop novel therapies for conditions affected by dysfunctional mitochondria, including Alzheimer’s and Parkinson’s diseases.
“The expertise we have assembled and the platform technologies we have created will allow new inroads into treating both rare genetic diseases as well as common diseases of aging,” said Jay Parrish, PhD, board chair and CEO of Pretzel, in a Sept. 12 company news release.
Pretzel’s scientific advisory board consists of two Nobel laureates. Arch Venture Partners and Mubadala Capital led the investment round.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.